Weekly Highlights: Sanofi and Novartis Leadership Changes; Li Li Appointed as Director of National Medical Products Administration
Sanofi
Pharmaceutical R&D Developer
Novartis
Drug Development and Manufacturing
RemeGen
Biological New Drug Developer
Junshi Biosciences
Innovative Drug Developer
CSPC
Developer of finished drugs and active pharmaceutical ingredients
MSD
Pharmaceutical R&D and Manufacturer
SINOMED
High-end interventional medical device R&D, production, and sales provider
Amgen
Developer of Treatment Drugs for Serious Diseases
"Weekly Highlights"
"Weekly Highlights" is a column launched by Siqi Club to summarize the major events in the pharmaceutical industry each week, covering the latest policy updates, news, pharmaceutical finance, and drug approval progress.
Personnel Changes
HUMAN RESOURCES
Sanofi Restructures, Creates Three New Positions
On September 1, Sanofi China announced on its official WeChat account that it would update its China strategy and organizational structure, establishing three new global management positions:
Shi Wang has been appointed as the President of Sanofi Greater China Region and will continue to report to Olivier Charmeil, Executive Vice President of Sanofi and Head of the Global Division of General Medicines.
Appointment of China R&D Head to Be Announced Soon;
Guoling He has been appointed as the Head of Made in China and Supply Chain, reporting to Brendan O'Callaghan, Executive Vice President of Sanofi and Head of Manufacturing and Supply Division.
Novartis Announces New Personnel Appointments
On September 6, Novartis announced that Marie-France Tschudin, the current President of International Innovative Medicines and Chief Commercial Officer, will step down from her position. She will also step down from the Novartis Executive Committee (ECN), effective September 15.
RemeGen Chief Financial Officer Resigns
On September 4, RemeGen announced that the board of directors received a written resignation letter from Mr. Li Jia, the company's Chief Financial Officer and Joint Company Secretary, on September 4, 2023. Due to personal career development reasons, Mr. Li Jia has applied to resign from his positions as Chief Financial Officer and Joint Company Secretary, and will no longer hold any position in the company after his resignation.
Within a Week, Two Major R&D Veterans Depart from Junshi Biosciences
On September 2, Junshi Biosciences issued an announcement: Mr. Feng Hui, the company's executive director and core technical personnel, applied to resign from the positions of Chief Operating Officer and all internal positions in subsidiaries for personal reasons on August 31, 2023. The day before Mr. Feng Hui submitted his resignation, Wu Hai also applied to step down as a non-executive director and will no longer hold any position in the company.
Policy Brief
POLICY
Li Li Appointed as Director of the National Medical Products Administration
According to the official website of the Ministry of Human Resources and Social Security on September 6, the State Council appointed and dismissed national staff, appointing Li Li as the Director of the National Medical Products Administration.
Pharmaceutical News Updates
PHARMA
CSPC's "Naruzumab" Approved for Marketing, Treating Giant Cell Tumor of Bone
On September 6, the official website of China's National Medical Products Administration (NMPA) announced that Narucizumab Injection, submitted by Shanghai GeneMab Biological Technology Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited, has been approved for marketing. It is indicated for the treatment of adult patients with giant cell tumor of bone who are not eligible for surgical resection or for whom surgical resection may lead to severe functional impairment.
The World's First FcRn Antagonist Efgartigimod Launched in China
On September 5, the world's first FcRn antagonist, Efgartigimod (Vyvgart®), was officially launched in China, benefiting patients with generalized myasthenia gravis in the country.
MSD's Nine-Valent HPV Vaccine New Indication Submitted for Market Approval
On September 5, the CDE website showed that MSD's Gardasil 9-valent Human Papillomavirus Vaccine (Saccharomyces cerevisiae) new indication marketing application was accepted.
Pharmaceutical Finance
BUSINESS
SINOMED to Acquire 72.73% Stake in U.S.-Based eLum for 1.52 Billion Yuan
On September 6, SINOMED announced that it plans to acquire 72.73% of eLum, a U.S.-based company, for $20,728,050 (approximately RMB 152 million). Founded in 2015, eLum is primarily engaged in the research, development, production, and sales of neurointerventional medical devices.
FTC Approves Amgen's Acquisition of Horizon Therapeutics
Recently, the FTC official website showed that Amgen's acquisition of Horizon Therapeutics was approved. However, according to the agreement, Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa for sale.
Guangzhou Improve Medical Instruments Co., Ltd. Withdraws 1.56 Billion Yuan Private Placement Plan
On the evening of September 5, Guangzhou Improve Medical Instruments Co., Ltd. announced that it would withdraw the application documents for a private placement aimed to raise 156 million yuan.
ClickRead the Original Text Learn More